A Study of Bimatoprost 0.01% in the Clinical Setting (APPEAL-Taiwan)

Pts with POAG or OH (Previously Treatment Naive)

Previously treatment naïve patients with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).

药品：Bimatoprost 0.01%

One drop of bimatoprost 0.01% (Lumigan® 0.01%) in the affected eye(s) every evening for 12 weeks.

其他名称：

• Lumigan® 0.01%

Pts with POAG or OH (Switched Monotherapy)

Patients previously on another monotherapy treatment with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).

药品：Bimatoprost 0.01%

One drop of bimatoprost 0.01% (Lumigan® 0.01%) in the affected eye(s) every evening for 12 weeks.

其他名称：

• Lumigan® 0.01%

Severity of Ocular Hyperemia in the Study Eye on a 5-Point Scale

Hyperemia is the engorgement of the blood vessels (redness) of the eye. Hyperemia is graded in the study eye on a 5-point scale where 0=None (Normal), 0.5=Trace (Trace reddish pink with no more than slight perilimbal injection), 1=Mild (Mild flush reddish color), 2=Moderate (Bright red color), and 3=Severe (Deep, bright, diffuse redness). The numbers of patients in each severity grade are presented.

Change From Baseline in Intraocular Pressure (IOP) in the Study Eye

IOP is a measure of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening).

Percentage of Patients Who Discontinue Due to an Adverse Event

An adverse event is any untoward medical occurrence associated with the use of a drug, whether or not considered drug related.

Overall Percent Change From Baseline in IOP

IOP is a measure of the fluid pressure inside the eye. A negative number change response indicates a reduction in IOP (improvement) and a positive number change response indicates an increase in IOP (worsening).